--- title: "Q32 Bio announces restructuring and workforce reduction to focus on bempikibart" url: "https://aibio.space/news/q32-bio-announces-restructuring-workforce-reduction-focus-bempikibart/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-02-10" section: "Distress" tickers: "NASDAQ:QTTB" source: "https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/qttb-20250210.htm" summary: "Q32 Bio is ending its renal trial of ADX-097, cutting staff and betting on bempikibart in alopecia areata. It expects about $1.1 million in severance charg" --- By the aibio.space news desk. Sources - [Q32 Bio Inc. Form 8-K filed February 10, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/qttb-20250210.htm) - [Q32 Bio Inc. exhibit qttb-ex99_1.htm to the February 10, 2025 Form 8-K (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/qttb-ex99_1.htm) [QTTB](https://aibio.space/companies/q32-bio/) 2025-02-10 # Q32 Bio announces restructuring and workforce reduction to focus on bempikibart Tickers [QTTB](https://aibio.space/companies/q32-bio/) Q32 Bio is ending its renal trial of ADX-097, cutting staff and betting on bempikibart in alopecia areata. It expects about $1.1 million in severance charges and says cash should last into the second half of 2026, but the release gives no cash balance. ## Key facts - **Company**: Q32 Bio Inc. (NASDAQ: QTTB) - **News type**: Distress - **Primary source**: [Q32 Bio Inc. Form 8-K filed February 10, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/qttb-20250210.htm) *A columned courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* Q32 Bio Inc. (Nasdaq: [QTTB](https://aibio.space/companies/q32-bio/)) told employees on February 10, 2025 about a strategic restructuring that includes a workforce reduction. The company is discontinuing its Phase 2 renal basket trial of ADX-097. It says the plan, with other cost cuts, should extend its cash runway to the second half of 2026. The company reported the plan in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/qttb-20250210.htm) filed the same day, under Item 2.05 for exit and disposal costs. ## What the company is cutting The board adopted the plan to focus resources on bempikibart in patients with alopecia areata. Along with the renal trial, Q32 Bio is evaluating strategic options for its tissue-targeted complement inhibitor platform, which includes ADX-097 and early-stage assets. The filing does not say which. The reduction in force is expected to be substantially complete by the end of the second quarter of 2025. The company expects severance and severance-related charges of about $1.1 million. It adds that it may incur other charges or cash expenditures it cannot yet estimate. The filing does not give the number of employees affected. ## The cash claim has no dollar figure behind it The press release says the restructuring, together with other cost-saving measures, is expected to extend cash runway to the second half of 2026. It credits ending the ADX-097 trial to conserve resources and cites lower personnel and related expenses. The release also warns that the company may need more funding to complete its clinical studies, and that the funding may not be available on favorable terms or at all. The release gives no cash balance and no burn rate, so the second-half 2026 date cannot be checked against a dollar figure. The runway is a management estimate. ## The bempikibart claims Bempikibart, also called ADX-914, is a fully human anti-IL-7Rα antibody in a Phase 2 program for autoimmune diseases. The company says Part A of its SIGNAL-AA Phase 2a trial in alopecia areata showed "encouraging clinical activity," including improvement from baseline on the Severity of Alopecia Tool, or SALT, score and a SALT-20 response through week 36. It says some patients continued to respond through week 55. The release does not give the number of patients in Part A, and it does not mention a placebo group. It also does not report how many patients met the SALT-20 response or how the change compares with any control. "Encouraging" is the company's own word for early Phase 2a data. Chief Executive Officer Jodie Morrison said the data reflect a well-tolerated safety profile, which the release also presents without a figure for adverse events. Based on re-consent rates and what it calls strong patient demand for continued dosing, Q32 Bio is starting an open-label extension in the first half of 2025. That extension is not controlled, so it cannot show whether the effect is due to the drug. The company also expects to start dosing in Part B of SIGNAL-AA in the first half of 2025, with topline data expected in the first half of 2026. Part B is also open-label, in approximately 20 evaluable patients with severe or very severe alopecia areata, who get bempikibart for 36 weeks with follow-up out to 52 weeks. The dosing is a loading regimen of 200mg weekly over four weeks, then 200mg every other week. ## What the restructuring means Q32 Bio is cutting staff and dropping the renal basket trial of ADX-097, its most advanced complement program. The company says it will focus on bempikibart, whose next readout is the open-label Part B data. The announcement brings no new money to the company. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story QTTB Q32 Bio Inc. NASDAQ · United States Open the starter desk ## More in Distress Distress ### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/) Oct 29, 2026 Distress ### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/) Oct 29, 2026 Distress ### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/) Oct 28, 2026 --- Source page: https://aibio.space/news/q32-bio-announces-restructuring-workforce-reduction-focus-bempikibart/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Q32 Bio announces restructuring and workforce reduction to focus on bempikibart", 2025-02-10, https://aibio.space/news/q32-bio-announces-restructuring-workforce-reduction-focus-bempikibart/